Persistent Depressive Disorder Research & Evidence-Based Practice 5 — Questions and Answers
Question 1: According to evidence-based practice principles, when a clinician encounters a PDD patient who has failed two adequate antidepressant trials, what should guide the next clinical decision?
- Systematic review of adequacy of prior trials, then consider augmentation, switching, or combination strategies per treatment algorithms (Correct answer)
- Immediately refer to inpatient psychiatric hospitalization
- Discontinue all medication and rely solely on psychotherapy
- Diagnose treatment-resistant depression and stop active treatment attempts
Correct answer: Systematic review of adequacy of prior trials, then consider augmentation, switching, or combination strategies per treatment algorithms
EBP requires first verifying prior trial adequacy (dose and duration), then systematically applying evidence-based algorithms for augmentation, switching, or combination strategies.
Question 2: Research on the epidemiology of PDD indicates what about its distribution across demographic groups in the US?
- PDD is approximately twice as prevalent in women as in men, similar to MDD (Correct answer)
- PDD affects men and women at equal rates unlike MDD
- PDD is most prevalent in the 65+ age group
- PDD is more common in men due to alexithymia masking symptoms in women
Correct answer: PDD is approximately twice as prevalent in women as in men, similar to MDD
Epidemiological research shows PDD follows a similar sex distribution to MDD, with approximately 2:1 female-to-male prevalence ratio in US population studies.
Question 3: A clinician practicing evidence-based care for PDD should monitor treatment response using which timeframe as the standard for assessing antidepressant adequacy?
- At least 4-8 weeks at therapeutic dose before concluding inadequate response (Correct answer)
- One week at any dose is sufficient to judge response
- 6 months minimum before any dose adjustment
- Antidepressants should never be changed; only augmented
Correct answer: At least 4-8 weeks at therapeutic dose before concluding inadequate response
Evidence-based guidelines specify that antidepressant trials require 4-8 weeks at therapeutic doses to adequately assess response, as earlier changes may prematurely abandon effective treatment.
Question 4: What does research on the chronobiology of PDD suggest about circadian rhythm disturbances?
- PDD is associated with disrupted circadian rhythms including delayed sleep phase and reduced amplitude of melatonin secretion (Correct answer)
- PDD has no identifiable circadian disturbances unlike seasonal affective disorder
- Circadian disruption in PDD is identical to that seen in bipolar disorder
- Only hypersomnia occurs in PDD; insomnia is not a chronobiological feature
Correct answer: PDD is associated with disrupted circadian rhythms including delayed sleep phase and reduced amplitude of melatonin secretion
Research shows PDD involves measurable circadian disruptions including delayed sleep phase and blunted melatonin secretion, supporting chronotherapeutic interventions as adjuncts.
Question 5: Evidence-based research on psychoeducation as a component of PDD treatment supports which conclusion?
- Psychoeducation improves treatment adherence and outcomes when combined with active treatment (Correct answer)
- Psychoeducation alone is sufficient treatment for mild PDD
- Psychoeducation has no measurable effect on treatment adherence
- Psychoeducation should only be provided to family members, not patients
Correct answer: Psychoeducation improves treatment adherence and outcomes when combined with active treatment
Research supports psychoeducation as a valuable component of PDD treatment, improving medication adherence, normalizing the chronic course, and enhancing engagement with therapy.
Question 6: Which research finding best supports the use of MAOI antidepressants in treatment-resistant PDD cases?
- MAOIs show efficacy in atypical depressive features common in chronic depression, including mood reactivity and rejection sensitivity (Correct answer)
- MAOIs are first-line agents due to superior safety profiles
- MAOIs specifically target the dopamine system implicated in PDD chronicity
- MAOIs are preferred because they lack drug interactions
Correct answer: MAOIs show efficacy in atypical depressive features common in chronic depression, including mood reactivity and rejection sensitivity
Research supports MAOI use in PDD with atypical features (mood reactivity, hypersomnia, rejection sensitivity), though dietary restrictions and drug interactions limit their use to treatment-resistant cases.
Question 7: A systematic review examining self-report instruments for PDD screening in research settings would most likely conclude which tool has the best combination of sensitivity and specificity?
- The Patient Health Questionnaire-9 (PHQ-9) with a cutoff adjusted for chronic presentations (Correct answer)
- The Hamilton Anxiety Rating Scale (HAM-A)
- The Mini-Mental State Examination (MMSE)
- The Yale-Brown Obsessive Compulsive Scale (Y-BOCS)
Correct answer: The Patient Health Questionnaire-9 (PHQ-9) with a cutoff adjusted for chronic presentations
The PHQ-9, with appropriate cutoff adjustment for chronic low-grade symptoms, has the strongest evidence base for depression screening in both clinical and research settings.
Persistent Depressive Disorder Research & Evidence-Based Practice 5
According to evidence-based practice principles, when a clinician encounters a PDD patient who has failed two adequate antidepressant trials, what should guide the next clinical decision?